

CURE OF HCV RELATED LIVER DISEASE

Yves Benhamou
Hôpital Pitié Salpêtrière
Paris

HCV Infection

Chronic Hepatitis 75%-85%

15%-20% Cirrhosis

**Decompensated
Cirrhosis
HCC**

20%

1%-4% yr

Almost All HCV-Infected Patients Can Achieve SVR

GT 1 – 6



F0 – F4



D. Cirrhosis



SVR → 90% = Cure of HCV Infection → 90%

Anti-HCV Treatment Objectives


1. Stop/reverse liver fibrosis progression
2. Prevent/reverse cirrhosis
3. Prevent liver decompensation and HCC
4. Reduce liver related mortality

HCV eradication may achieve these objectives?

Fibrosis regression

IFN based therapy experience

Fibrosis « survival » according to virologic response: Proportion of patients without fibrosis regression using FibroTest ($\rightarrow 0,20$)




n = 719
P < 0.001

Fibrosis regression


IFN based therapy experience

Fibrosis degree at a second biopsy 5 years after SVR (n=122) grouped according to the degree of fibrosis at first biopsy



Cirrhosis reversion


IFN based therapy experience



Liver Decompensation

IFN based therapy experience


Proportion of liver decompensation according to virologic response



Liver Decompensation

IFN based therapy experience


Proportion of liver failure according to virologic response



No. at risk	0	1	2	3	4	5	6	7	8	9	10
Without SVR	405	384	361	337	314	288	259	216	184	143	113
With SVR	192	180	166	160	152	141	123	88	56	40	28

Hepatocellular Carcinoma


IFN based therapy experience



No. at risk	0	1	2	3	4	5	6	7	8	9	10
Without SVR	405	390	375	349	326	294	269	229	191	151	122
With SVR	192	181	167	161	152	142	124	86	54	39	27


Hepatocellular Carcinoma

IFN based therapy experience




Hepatocellular Carcinoma

IFN based therapy experience




Liver Related Mortality

IFN based therapy experience



Timothy RM. et al. *Hepatology* 2010



Van der Meer AJ. et al. *JAMA* 2012

HCV CURE

FIBROSIS REGRESSION

HCV CURE

CIRRHOSIS REVERSION
50%-60% at 5 yrs

HCV CURE

LD PREVENTION

HCV CURE

HCC PREVENTION
5-10 fold risk reduction

HCV CURE

MORTALITY REDUCTION
2-3 fold risk reduction



HCV CURE

FIBROSIS REGRESSION

HCV CURE

CIRRHOSIS REVERSION
50%-60% at 5 yrs

HCV CURE

LD PREVENTION

HCV CURE

HCC PREVENTION
5-10 fold risk reduction

HCV CURE

MORTALITY REDUCTION
2-3 fold risk reduction

**DA
A**
90%+ SVR



**HCV
CUR
E**



- Residual proportion of patients (1-7%) may not normalize ALT despite SVR and are at risk of progression to cirrhosis, LD↑ or HCC
 - Investigations for other causes (NASH, Drug-induced hepatotoxicity, Alcohol abuse ...)
- Cirrhosis may not reverse in all the cases
 - HCC screening advised
 - Cirrhosis reversion monitoring using non invasive methods
- Viral hepatitis represent only ~2/3 of liver diseases